Natco Pharma receives ANDA approval from USFDA

Natco Pharma receives ANDA approval from USFDA

Amir Shaikh
/ Categories: Trending

Natco Pharma today announced that it has received a final approval for its first supplemental abbreviated new drug application (ANDA) product from US Food & Drug Administration (USFDA) filed from its new drug formulation facility in JNPC SEZ, Ramky Pharma City, Visakhapatnam (Andhra Pradesh). 

ANDA, submitted as ‘prior approval supplement’, provides for NATCO's Visakhapatnam facility as an alternate site for the manufacture of the approved drug product for US market.

Earlier this week, the company had received a closure of inspection with an establishment inspection report (EIR) from US Food & Drug Administration (FDA) for the pre-approval inspection conducted at its drug formulations facility in Kothur village (Telangana) during the period from March 2 to March 6, 2020.

For more information, click here:

https://www.dsij.in/DSIJArticleDetail/ArtMID/10163/ArticleID/12597/USFDA-grants-EIR-to-Natco-Pharma-for-Kothur-facility

The stock of Natco Pharma reacted positively and surged to an intraday high of Rs 640.6 apiece.

 

Previous Article Ten stocks close to their 52-week high
Next Article Axis Bank & Max Financial to form 30:70 JV in Max Life
Rate this article:
3.3

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList